- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01478373
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
26. april 2016 oppdatert av: Novartis Pharmaceuticals
DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
The purpose of this study is to evaluate the efficacy and safety of Dovitinib in patients with gastrointestinal stromal tumors refractory and/or intolerant to Imatinib
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
39
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
HUS, Finland, FIN-00029
- Novartis Investigative Site
-
-
-
-
-
Bordeaux, Frankrike, 33076
- Novartis Investigative Site
-
Lille Cedex, Frankrike, 59020
- Novartis Investigative Site
-
Lyon Cedex, Frankrike, 69373
- Novartis Investigative Site
-
Reims, Frankrike, 51092
- Novartis Investigative Site
-
Villejuif Cedex, Frankrike, 94805
- Novartis Investigative Site
-
-
-
-
MI
-
Milano, MI, Italia, 20133
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italia, 00168
- Novartis Investigative Site
-
-
TO
-
Candiolo, TO, Italia, 10060
- Novartis Investigative Site
-
Torino, TO, Italia, 10153
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spania, 08041
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spania, 08035
- Novartis Investigative Site
-
Hospitalet de LLobregat, Catalunya, Spania, 08907
- Novartis Investigative Site
-
-
Islas Baleares
-
Palma De Mallorca, Islas Baleares, Spania, 07120
- Novartis Investigative Site
-
-
-
-
-
Essen, Tyskland, 45147
- Novartis Investigative Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Histologically confirmed GIST of any anatomical location, which is 1) unresectable and/ or metastatic with documented disease progression while on therapy with imatinib or 2) surgically removed localized GIST, recurrent on adjuvant imatinib or recurrent within the first 3 months after discontinuation of adjuvant imatinib or 3) patients with unresectable and/or metastatic GIST intolerant to imatinib
- Positive immunohistochemical staining for c-KIT (CD117); or negative staining for KIT, but with either positive staining for DOG1 or an identified mutation of KIT or PDGFRA gene
- Documented disease progression according to RECIST (version 1.1) on prior therapy with imatinib at a dose of at least 400mg/day or patients with unresectable and/or metastatic GIST who are intolerant to imatinib
- At least one measurable GIST lesion according to RECIST (version 1.1).
- Adequate bone marrow, liver and renal function
Exclusion Criteria:
- Patients who have received any other tyrosine-kinase inhibitor but imatinib for GIST
- Patients who received cytotoxic drugs ≤ 4 weeks prior to starting Dovitinib (TKI258)
- Patients who are treated or planned to be treated concomitantly with other cytotoxic or antineoplastic treatments, such as chemotherapy, immunotherapy, biological response modifiers, or radiotherapy
- Patients with another primary malignancy within 3 years prior to starting the study drug
- Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic) ≤ 4 weeks prior to starting Dovitinib (TKI258) or who have not recovered from the adverse effects of such therapy
- Patients with a history of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) within the past 6 months
- Patients with impaired cardiac function or clinically significant cardiac diseases
- Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of Dovitinib
- Patients with prior complete gastrectomy
- Patients with brain metastasis or history of brain metastasis
- Patients who are currently receiving anticoagulation treatment with therapeutic doses of warfarin or equivalent anticoagulant
- Pregnant or breast-feeding women
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Dovitinib (TKI258)
Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
|
Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease
Tidsramme: 12 Weeks
|
DCR is defined as the proportion of patients with a best overall response of Complete Responses (CR), Partial Response (PR) and Stable Disease (SD) at 12 weeks according to RECIST (version 1.1).
Complete Response (CR): Disappearance of all non-nodal target lesions.
In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
|
12 Weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Progression-free Survival (PFS) of Patients Treated With Dovitinib
Tidsramme: 9 months
|
The PFS duration: time from entry into the study to the date of the first documented progression (assessed using conventional RECIST (version 1.1) or death due to any cause.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
9 months
|
Time to Treatment Failure (TTF)of Patients Treated With Dovitinib
Tidsramme: 9 months
|
TTF: the date of entry into the study to the earliest date of the first objective tumor progression, date of death due to any cause, or date of discontinuation due to reasons other than 'Protocol deviation' or 'Administrative problems'.
|
9 months
|
Duration of Response or Stable Disease (SD)
Tidsramme: 9 months
|
Duration of response or SD: time from date of entry into study to earliest date of first objective tumor progression or death.
DCR is defined as proportion of patients with best overall response of CR, PR and SD at 12 weeks according to RECIST (version 1.1).
CR: Disappearance of all non-nodal target lesions.
Any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1; PR: At least a 30% decrease in sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
PD: At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
|
9 months
|
Time to Tumor Progression (TTP)of Patients Treated With Dovitinib
Tidsramme: 9 months
|
TTP: time from the date of entry into the study to first documentation of tumor progression or death due to the underlying cancer.
Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
9 months
|
Overall Response Rate (ORR) of Patients Treated With Dovitinib
Tidsramme: Baseline, 12 weeks
|
Outcome Measure Description: ORR: proportion of patients whose best overall response is either complete response (CR) or partial response (PR) according to RECIST (version 1.1).
Complete Response (CR): Disappearance of all non-nodal target lesions.
In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
|
Baseline, 12 weeks
|
Overall Survival (OS) of Patients Treated With Dovitinib
Tidsramme: 21 months (9 months of estimated treatment plus 12 months of survival follow up)
|
Outcome Measure Description: OS: time from the date of entry into the study to the date of death due to any cause.
A patient who has not died by the date of the analysis cut-off would have the OS censored at the time of the last contact before the cut-off date.
|
21 months (9 months of estimated treatment plus 12 months of survival follow up)
|
DCR (CR+PR+SD) at the End of Treatment
Tidsramme: Up to 9 months of estimated treatment
|
DCR is defined as the proportion of patients with a best overall response of CR, PR and SD at the end of dovitinib treatment according to RECIST (version 1.1).
Complete Response (CR): Disappearance of all non-nodal target lesions.
In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1;Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline.
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD.
|
Up to 9 months of estimated treatment
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2012
Primær fullføring (Faktiske)
1. juli 2014
Studiet fullført (Faktiske)
1. juli 2014
Datoer for studieregistrering
Først innsendt
16. november 2011
Først innsendt som oppfylte QC-kriteriene
21. november 2011
Først lagt ut (Anslag)
23. november 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
27. april 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
26. april 2016
Sist bekreftet
1. april 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CTKI258AIC02
- 2011-001725-24 (EudraCT-nummer)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Gastrointestinale stromale svulster
-
Centre Leon BerardRekrutteringMetastatisk gastrointestinal stromal svulst | Ikke-opererbar gastrointestinal stromal tumor (GIST) | Lokalt avansert gastrointestinal stromal tumor (GIST)Frankrike
-
Hospital Universitario Virgen de la ArrixacaHar ikke rekruttert ennåLeversykdommer | Levertransplantasjon | Neoplasmer i leveren | Gastrointestinale stromale svulster | Metastase | Levermetastaser | Levertransplantasjon; Komplikasjoner | Leverkreft | Levertransplantasjonslidelse | Leverkarsinom | GIST, ondartet | GIST | Metastaser | Metastatisk leverkreft | Gastrointestinal stromal svulst... og andre forholdSpania
-
Centre Leon BerardRekrutteringC-KIT-mutasjon | Metastatisk gastrointestinal stromal tumor (GIST) | Avansert gastrointestinal stromal tumor (GIST)Frankrike
-
ARCAGY/ GINECO GROUPRoche Pharma AGFullført
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk gastrointestinal stromal svulst | Metastatisk sarkom | Lokalt avansert sarkom | Lokalt avansert gastrointestinal stromal svulst | Stage III Gastrisk og Omental Gastrointestinal Stromal Tumor AJCC v8 | Trinn III Tynntarm, esophageal, kolorektal, mesenterisk og peritoneal gastrointestinal... og andre forholdForente stater
-
Deciphera Pharmaceuticals LLCAktiv, ikke rekrutterendeGIST - Gastrointestinal Stromal TumorForente stater
-
Deciphera Pharmaceuticals LLCGodkjent for markedsføringGIST - Gastrointestinal Stromal Tumor
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Dana-Farber Cancer Institute; University of...FullførtAvansert gastrointestinal stromal tumor (GIST)Forente stater
-
Beihua KongSun Yat-sen University; Huazhong University of Science and Technology; Zhejiang...RekrutteringNeoplasmer i eggstokkene | Eggstokkreft | Ovarial Sex Core Stromal TumorKina
-
Children's Hospitals and Clinics of MinnesotaM.D. Anderson Cancer Center; Massachusetts General Hospital; Washington University... og andre samarbeidspartnereRekrutteringSmåcellet ovariekarsinom | Testikkelstromale svulster | Ovarial Sex-cord Stromal TumorForente stater
Kliniske studier på Dovitinib (TKI258)
-
Novartis PharmaceuticalsFullførtNeoplasmer | Kreft | TumorerForente stater
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreftForente stater, Canada, Finland, Frankrike, Italia, Spania, Taiwan, Storbritannia
-
M.D. Anderson Cancer CenterNovartisAvsluttet
-
Korean Cancer Study GroupFullførtHormonrefraktær prostatakreftKorea, Republikken
-
Novartis PharmaceuticalsFullførtTumor Pathway Activations inhibited by DovitinibForente stater
-
Novartis PharmaceuticalsFullførtLivmorkreft | VEGF | Solide svulster og avansert endometriekreft | Andrelinjes behandlingItalia, Storbritannia, Spania, Brasil, Forente stater, Korea, Republikken, New Zealand
-
Auckland District Health BoardNovartis; University of Auckland, New Zealand; IGENZ, Ltd., AucklandUkjentKlarcellet nyrecellekarsinomNew Zealand
-
Novartis PharmaceuticalsFullførtAvanserte solide svulster | Unntatt brystkreftForente stater
-
Novartis PharmaceuticalsFullførtKreft | Neoplasma | TumorerForente stater
-
Novartis PharmaceuticalsFullført